- Investing.com
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
CRO Market Dynamics | Explore ICON's position in the volatile CRO industry, facing cancellations and budget constraints while leveraging its global scale and technological edge |
Financial Crossroads | Delve into ICON's mixed financial performance, with recent bookings misses and guidance revisions, against a backdrop of strong historical metrics |
Strategic Resilience | Learn how ICON's proprietary capabilities and market positioning could drive future growth amid industry headwinds and potential biopharma spending rebound |
Valuation Insights | Analyst targets range from $155 to $263, with potential for re-rating towards historical P/E multiples as transient challenges subside |
Metrics to compare | ICLR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICLRPeersSector | |
---|---|---|---|---|
P/E Ratio | 17.8x | 21.5x | −0.5x | |
PEG Ratio | 1.35 | 0.07 | 0.00 | |
Price/Book | 1.5x | 2.0x | 2.6x | |
Price / LTM Sales | 1.7x | 1.7x | 3.3x | |
Upside (Analyst Target) | 22.4% | 56.0% | 42.4% | |
Fair Value Upside | Unlock | 18.5% | 7.2% | Unlock |